A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 109, Issue 10, Pages 2574-2578
Publisher
Springer Nature
Online
2013-10-23
DOI
10.1038/bjc.2013.648
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study on lapatinib in advanced EGFR-positive chordoma†
- (2013) S. Stacchiotti et al. ANNALS OF ONCOLOGY
- Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors
- (2012) L. Schirosi et al. ANNALS OF ONCOLOGY
- Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
- (2012) A. Awada et al. ANNALS OF ONCOLOGY
- Phase II Study of Imatinib in Advanced Chordoma
- (2012) Silvia Stacchiotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma
- (2012) Yuanlin Xu et al. LEUKEMIA & LYMPHOMA
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
- (2011) G Bousquet et al. BRITISH JOURNAL OF CANCER
- Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
- (2011) Stéphane Bouchet et al. CLINICA CHIMICA ACTA
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- (2011) M.J.A. de Jonge et al. EUROPEAN JOURNAL OF CANCER
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
- (2010) N. Penel et al. ANNALS OF ONCOLOGY
- Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
- (2010) N Penel et al. BRITISH JOURNAL OF CANCER
- Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
- (2010) P Hamberg et al. BRITISH JOURNAL OF CANCER
- Proposal for size justification of expanded cohort at phase-2-recommended dose
- (2010) Nicolas Penel et al. INVESTIGATIONAL NEW DRUGS
- A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors
- (2010) Christopher J. Sweeney et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More